All GLG News Analyses Filed Under: Oncology

The epidermal growth factor antagonist Erbitux did not improve response rates in newly diagnosed patients with advanced non-small cell lung cancer ( NSCLC).  Many patients had hypersensitivity reactions to Cetuximab, which has to be content with its role in colon cancer treatment and to some extent...

This article has many biases. However, the important message NOT mentioned is the technology is not the cause of the scarring issues, but the surgeons technique. In my capacity performing this surgery both with and without the robot the learning curve for surgeons can be causal. Also from a non-technical...

Higher recurrance rate???!!!

     While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) &  Avant/Pfizer  vaccines  are making an impact on  "Brain Cancer"  survival.

Proteolix's selective proteosome inhibitor PR-171 have shown pre-clinical activity in slid tumor animal models, but only a small Phase Ib clinical trial of 14 patients have been completed. based on spectrum of activity of a similar compound ( Valcade, Mellinium), the main efficacy of this agent...

Erbitux has had a few high level trials in Non small lung cancer So far there does not appear to be a contributuion to chemotherapy Maybe we are going about it the wrong way

" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.

As world economies improve more money will be spent globally on cancer care expanding potential markets

Carfilzomib is a nvelo prteosome inhibitor.  Bortezomib, the only proteosome inhibitor that is currently FDA approve, has shown significant activity in myeloma and mantle cell NHL and is being tested in other hematologic malignancies.  If Carfilzomib has improved toxicty and greater efficacy...

The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.